NCT06761599Active, not recruiting
Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 7 Jan 2025
Brief summary (registry, in English)
Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 214 (actual)
- First submitted
- 19 Dec 2024
- Start date
- 18 Feb 2024
- Primary completion date
- 15 Jul 2024
- Lead sponsor
- Superior University
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06761599
What you commit to
- Study type: Observational
- Participants enrolled: 214
- From 18 Feb 2024 to the primary completion date, 15 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a diagnosis of another malignancy.
- Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis.
Other
- Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments.
- Patients who are unable to complete pulmonary function tests.
Who the study is looking for
- Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment.
- Patients of all ages and both genders.
- Patients with histologically confirmed HL, as per the WHO 2016 classification.
- Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course.
- Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shaukat Khanum Memorial Cancer Hospital and Research Centre, 5-B, Sector A2, Phase 5, Hayatabad Coordinator of this site? Confirm its status | Peshawar | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.